Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which nerve block eases hip surgery pain better?

NCT ID NCT07771829

Symptom relief Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This trial compares two ultrasound-guided nerve block techniques for pain control after total hip replacement surgery. One technique, the QLESP block, uses a single injection to target two areas, while the other combines two blocks (PENG and LFCN) to target nerves around the hip and outer thigh. Participants are randomly assigned to receive one of the two blocks after surgery. The study measures pain scores, opioid use, leg movement recovery, time to first walk, and hospital stay length to see which approach offers better pain relief and faster recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two nerve block techniques: QLESP block (single injection targeting two areas) versus PENG+LFCN block (two injections targeting hip and thigh nerves), using the local anesthetic ropivacaine.
What this could lead to
If one nerve block proves better, it could lead to improved pain control and faster recovery after hip replacement surgery, reducing the need for opioids.
What could go wrong
The trial is relatively small and early-stage, so results may not apply to all patients. Nerve blocks carry risks like infection, bleeding, or nerve damage, and pain relief may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 70 years * Scheduled for elective unilateral total hip arthroplasty via posterolateral approach * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) \< 35 kg/m² * Ability to understand pain scoring and patient-controlled analgesia (PCA) use * Willing and able to provide written informed consent Exclusion Criteria: * Allergy or hypersensitivity to local anesthetics (ropivacaine) * Long-term opioid use or chronic pain history requiring regular analgesic use * Active malignancy or infection at the puncture site * Severe psychiatric disorders or communication barriers * Severe cardiopulmonary disease * History of opioid abuse or substance dependence * Participation in another interventional clinical trial within 3 months prior to enrollment * Coagulation abnormalities * Pregnancy or breastfeeding * Any condition that, in the investigator's opinion, would compromise patient safety or data integrity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty total hip replacement are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthroplasty total hip replacement Pain management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.